Bei Akademie registrieren
MRVI, US56600D1072

Maravai LifeSciences stock gets November conference update

Published on 10/30/2026 at 02:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Lang & Schwarz quoted the share at EUR 7.55 at 10:59 p.m. Berlin time on October 29. The Maravai LifeSciences stock faces new investor events in November.

Conference plans and investor context

  • Maravai CFO Raj Asarpota is scheduled to participate in healthcare conferences in New York and London.
  • The company says live webcasts and archived versions will be available through its investor-relations website.
  • The events give investors an opportunity to hear directly from management after the second-quarter update.
MRVI, US56600D1072, Illustration mit AI erstellt.
MRVI, US56600D1072, Illustration mit AI erstellt.

Maravai LifeSciences has scheduled appearances at two healthcare investor conferences in November, giving management another opportunity to discuss the company with institutional investors. The announcement was issued on October 29 and published by Business Wire via Yahoo Finance.

Management appearances in November

Raj Asarpota, Maravai LifeSciences' executive vice president and chief financial officer, is scheduled to join a fireside chat at the Stifel Healthcare Conference in New York on November 12. He is also scheduled to participate in a fireside chat at the Jefferies Healthcare Conference in London on November 17.

The company said live webcasts of both presentations will be available through the Maravai LifeSciences investor-relations website under News & Events and the IR Calendar. Archived versions are expected to remain available after the events.

What investors can monitor

The conference schedule does not provide new financial guidance or operating results. It does, however, create a defined opportunity for investors to assess management's comments on demand for nucleic-acid products, biologics safety testing, margins and the company's broader life-sciences strategy.

Maravai previously reported second-quarter 2026 revenue of USD 51.44 million, according to the company's recent investor communications summarized in the available market coverage. The next scheduled results date shown on the company's topic page is November 4, 2026, so the conference appearances will follow the next results update.

Lang & Schwarz quoted the share at EUR 7.55 on October 29, 2026, at 10:59 p.m. Berlin time. The available data did not provide a verified Xetra closing comparison for the same instrument, so no Xetra-based daily percentage is stated.

The Realtime-Kurs der Maravai LifeSciences-Aktie provides the latest available quote information.

For the broader US market context, investors can follow the S&P 500 without treating index performance as a company-specific signal.

Further company developments are collected in More news and analyses on Maravai LifeSciences stock.

Maravai LifeSciences at a glance

  • Company: Maravai LifeSciences
  • ISIN: US56600D1072
  • Ticker: MRVI
  • Market: Nasdaq
  • Lang & Schwarz quote: EUR 7.55 on October 29, 2026, at 10:59 p.m. Berlin time
Disclaimer...
en | US56600D1072 | MRVI | boerse | 70432091 |